This would be particularly important for the effective targeting of CAR antigen–low disease, and would potentially mitigate subsequent CAR target–low relapse often seen in KMT2Ar-ALL and other forms of ALL treated with CD19 CAR T cells.8 The gene discussed is CD19; the disease is acute lymphoblastic leukemia.